Robert R Conley

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi The burden of depressive symptoms in people with schizophrenia
    Robert R Conley
    Eli Lilly and Company, US Medical Division, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Psychiatr Clin North Am 32:853-61. 2009
  2. ncbi Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms
    Virginia L Stauffer
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Schizophr Res 134:195-201. 2012
  3. ncbi Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia
    John P Houston
    Eli Lilly and Company, Indianapolis, Indiana, USA
    J Clin Psychiatry 73:1077-86. 2012
  4. ncbi Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, IN, USA
    J Med Econ 15:531-47. 2012
  5. ncbi Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone
    Bonnie A Fijal
    Lilly USA, Indianapolis, IN 46285, USA
    J Clin Psychiatry 73:367-71. 2012
  6. ncbi Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia
    Stephen J Ruberg
    Eli Lilly and Company, Indianapolis, IN, USA
    BMC Psychiatry 11:23. 2011
  7. ncbi Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model
    Nicolas M Furiak
    Medical Decision Modeling Inc, Indianapolis, IN, USA
    Curr Med Res Opin 27:713-30. 2011
  8. ncbi Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controll
    Vicki P Hoffmann
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 30:656-60. 2010
  9. ncbi Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia
    Xiaomei Peng
    Eli Lilly and Company, Indianapolis, IN, USA
    Clinicoecon Outcomes Res 3:9-14. 2011
  10. ncbi The cost of relapse and the predictors of relapse in the treatment of schizophrenia
    Haya Ascher-Svanum
    US Outcomes Research, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 10:2. 2010

Detail Information

Publications10

  1. ncbi The burden of depressive symptoms in people with schizophrenia
    Robert R Conley
    Eli Lilly and Company, US Medical Division, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Psychiatr Clin North Am 32:853-61. 2009
    ..Furthermore, changes in depressed status were associated with changes in functional outcomes...
  2. ncbi Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms
    Virginia L Stauffer
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Schizophr Res 134:195-201. 2012
    ..This distinction, incorporating an evaluation of the presence of positive, affective, and extrapyramidal symptoms, may therefore not have prognostic implications for the responsiveness of patients' negative symptoms to treatment...
  3. ncbi Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia
    John P Houston
    Eli Lilly and Company, Indianapolis, Indiana, USA
    J Clin Psychiatry 73:1077-86. 2012
    ..We assessed the relationships between single-nucleotide polymorphisms (SNPs) in these genes with weight gain during treatment with olanzapine in a predominantly antipsychotic-naive population...
  4. ncbi Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, IN, USA
    J Med Econ 15:531-47. 2012
    ..The study also compared olanzapine ODT with risperidone and aripiprazole, two other atypical antipsychotics available in both ODT and SOT formulations...
  5. ncbi Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone
    Bonnie A Fijal
    Lilly USA, Indianapolis, IN 46285, USA
    J Clin Psychiatry 73:367-71. 2012
    ..We examined 6 single nucleotide polymorphisms (SNPs) previously reported to be associated with response to iloperidone therapy for association with response to risperidone therapy...
  6. ncbi Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia
    Stephen J Ruberg
    Eli Lilly and Company, Indianapolis, IN, USA
    BMC Psychiatry 11:23. 2011
    ..To identify a simple decision tree using early symptom change to predict response to atypical antipsychotic therapy in patients with (Diagnostic and Statistical Manual, Fourth Edition, Text Revised) chronic schizophrenia...
  7. ncbi Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model
    Nicolas M Furiak
    Medical Decision Modeling Inc, Indianapolis, IN, USA
    Curr Med Res Opin 27:713-30. 2011
    ....
  8. ncbi Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controll
    Vicki P Hoffmann
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 30:656-60. 2010
    ..Clinical monitoring is advised throughout treatment for all patients...
  9. ncbi Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia
    Xiaomei Peng
    Eli Lilly and Company, Indianapolis, IN, USA
    Clinicoecon Outcomes Res 3:9-14. 2011
    ..To assess change in hospitalization and cost of care from 6 months pre- to 6 months post-initiation on any depot antipsychotic among schizophrenia patients...
  10. ncbi The cost of relapse and the predictors of relapse in the treatment of schizophrenia
    Haya Ascher-Svanum
    US Outcomes Research, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 10:2. 2010
    ..To assess the direct cost of relapse and the predictors of relapse during the treatment of patients with schizophrenia in the United States...